Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Agios Pharmaceuticals Inc. (AGIO) Insider Trading Activity
Healthcare • Biotechnology • 383 employees
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Total Value
-$2,899,288.91
Total Shares
38,546
Average Trade Value
-$63,028.02
Most Active Insider
Ballal Rahul D.
Total Activity: $1,636,947
Largest Single Transaction
$697,372
by Burns James William on Nov 7, 2024
30-Day Activity
28 Transactions
Volume: 45,843 shares
Value: $844,227
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Financial Officer
Officer
|
Mar 3, 2025 | 1,681 | $59,743 | 25,829 (-6.5%) | Sale | |
|
Chief Legal Officer
Officer
|
Mar 3, 2025 | 1,137 | $40,409 | 18,650 (-6.1%) | Sale | |
|
Chief Legal Officer
Officer
|
Mar 3, 2025 | 1,187 | $42,186 | 21,463 (-5.5%) | Sale | |
|
Chief Legal Officer
Officer
|
Mar 3, 2025 | 1,681 | $59,743 | 25,449 (-6.6%) | Sale | |
|
Chief Medical Officer
Officer
|
Mar 3, 2025 | 1,137 | $40,409 | 47,098 (-2.4%) | Sale | |
|
Principal Accounting Officer
Officer
|
Mar 3, 2025 | 231 | $8,210 | 6,038 (-3.8%) | Sale | |
|
Chief Medical Officer
Officer
|
Mar 3, 2025 | 1,681 | $59,743 | 53,897 (-3.1%) | Sale | |
|
Principal Accounting Officer
Officer
|
Mar 3, 2025 | 727 | $25,838 | 9,414 (-7.7%) | Sale | |
|
Chief Medical Officer
Officer
|
Mar 3, 2025 | 1,187 | $42,186 | 49,911 (-2.4%) | Sale | |
|
Principal Accounting Officer
Officer
|
Mar 3, 2025 | 697 | $24,771 | 7,691 (-9.1%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Mar 3, 2025 | 4,153 | $147,598 | 83,139 (-5.0%) | Sale | |
|
Chief Executive Officer
Director, Officer
|
Mar 3, 2025 | 8,794 | $312,539 | 92,345 (-9.5%) | Sale | |
|
Chief Commercial Officer
Officer
|
Mar 3, 2025 | 1,681 | $59,743 | 22,892 (-7.3%) | Sale | |
|
Chief Financial Officer
Officer
|
Mar 3, 2025 | 594 | $21,111 | 21,843 (-2.7%) | Sale | |
|
Chief Medical Officer
Officer
|
Mar 1, 2025 | 4,000 | $10,000 | 51,098 (+7.8%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Mar 1, 2025 | 5,667 | $10,000 | 27,510 (+20.6%) | Exercise/Conversion | |
|
Chief Commercial Officer
Officer
|
Mar 1, 2025 | 5,667 | $10,000 | 24,573 (+23.1%) | Exercise/Conversion | |
|
Principal Accounting Officer
Officer
|
Mar 1, 2025 | 2,350 | $10,000 | 8,388 (+28.0%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Mar 1, 2025 | 2,000 | $0 | 22,437 (+8.9%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Mar 1, 2025 | 18,000 | $10,000 | 101,139 (+17.8%) | Exercise/Conversion | |
|
Chief Legal Officer
Officer
|
Mar 1, 2025 | 3,833 | $0 | 19,787 (+19.4%) | Exercise/Conversion | |
|
Chief Legal Officer
Officer
|
Mar 1, 2025 | 4,000 | $10,000 | 22,650 (+17.7%) | Exercise/Conversion | |
|
Chief Executive Officer
Director, Officer
|
Mar 1, 2025 | 8,500 | $10,000 | 87,292 (+9.7%) | Exercise/Conversion | |
|
Principal Accounting Officer
Officer
|
Mar 1, 2025 | 2,450 | $10,000 | 10,141 (+24.2%) | Exercise/Conversion | |
|
Chief Legal Officer
Officer
|
Mar 1, 2025 | 5,667 | $10,000 | 27,130 (+20.9%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Mar 1, 2025 | 5,667 | $10,000 | 55,578 (+10.2%) | Exercise/Conversion | |
|
Chief Medical Officer
Officer
|
Mar 1, 2025 | 3,833 | $0 | 48,235 (+7.9%) | Exercise/Conversion | |
|
Principal Accounting Officer
Officer
|
Mar 1, 2025 | 777 | $0 | 6,269 (+12.4%) | Exercise/Conversion | |
|
Principal Accounting Officer
Officer
|
Feb 5, 2025 | 2,272 | $78,134 | 5,437 (-41.8%) | Sale | |
|
Principal Accounting Officer
Officer
|
Feb 1, 2025 | 6,896 | $10,000 | 7,709 (+89.5%) | Exercise/Conversion | |
|
Chief Commercial Officer
Officer
|
Jan 6, 2025 | 2,804 | $90,233 | 18,906 (-14.8%) | Sale | |
|
Chief Commercial Officer
Officer
|
Jan 3, 2025 | 8,476 | $10,000 | 21,710 (+39.0%) | Exercise/Conversion | |
|
Director
|
Dec 11, 2024 | 200 | $3,618 | 15,683 (+1.3%) | Exercise/Conversion | |
|
Director
|
Dec 11, 2024 | 200 | $9,256 | 15,483 (-1.3%) | Sale | |
|
Director
|
Nov 8, 2024 | 3,571 | $204,404 | 14,421 (-24.8%) | Sale | |
|
Director
|
Nov 8, 2024 | 4,929 | $288,692 | 9,492 (-51.9%) | Sale | |
|
Director
|
Nov 8, 2024 | 10,000 | $259,900 | 17,992 (+55.6%) | Exercise/Conversion | |
|
Director
|
Nov 8, 2024 | 1,500 | $88,815 | 7,992 (-18.8%) | Sale | |
|
Principal Accounting Officer
Officer
|
Nov 8, 2024 | 772 | $43,301 | 813 (-95.0%) | Sale | |
|
Chief Legal Officer
Officer
|
Nov 7, 2024 | 13,411 | $697,372 | 24,041 (-55.8%) | Sale | |
|
Director
|
Nov 7, 2024 | 8,132 | $433,598 | 9,860 (-82.5%) | Sale | |
|
Director
|
Nov 7, 2024 | 1,868 | $101,638 | 7,992 (-23.4%) | Sale | |
|
Chief Legal Officer
Officer
|
Nov 7, 2024 | 8,341 | $438,403 | 15,700 (-53.1%) | Sale | |
|
Director
|
Nov 7, 2024 | 10,000 | $259,900 | 17,992 (+55.6%) | Exercise/Conversion | |
|
Chief Financial Officer
Officer
|
Sep 26, 2024 | 2,542 | $124,634 | 20,158 (-12.6%) | Sale | |
|
Chief Financial Officer
Officer
|
Sep 26, 2024 | 7,473 | $0 | 22,700 (+32.9%) | Exercise/Conversion |